Posted by Michael Wonder on 09 May 2023
Rhythm Pharmaceuticals announces Health Canada approval of Imcivree setmelanotide injection for weight management in Bardet-Biedl syndrome or genetically-confirmed biallelic POMC, PCSK1, or LEPR deficiency
8 May 2023 - Approval granted following a priority review by Health Canada.
Rhythm Pharmaceuticals today announced that Health Canada has approved Imcivree (setmelanotide solution for subcutaneous injection) for weight management in adult and paediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome or genetically-confirmed biallelic pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance.
